Dublin, Jan. 28, 2025 (GLOBE NEWSWIRE) -- The "CD39 Targeted Therapies Clinical Trials, Therapeutic Approaches & Market Opportunity Insight 2025" report has been added to ResearchAndMarkets.com's ...
Moderate expression of CD39 in GPC3-CAR-T cells shows high efficacy against hepatocellular carcinoma
In the quest to enhance the efficacy of chimeric antigen receptor T (CAR-T) cell therapy against hepatocellular carcinoma (HCC), a study in Frontiers of Medicine has identified a pivotal role for CD39 ...
BOSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer ...
In the quest to enhance the efficacy of chimeric antigen receptor T (CAR-T) cell therapy against hepatocellular carcinoma (HCC), a recent study has identified a pivotal role for CD39 expression in ...
NEW ORLEANS -- More than 60% of patients with unresectable gastric/gastroesophageal junction (GEJ) cancer responded to the combination of a CD39 inhibitor and chemoimmunotherapy, a small clinical ...
Adding an anti-CD39 monoclonal antibody to standard treatment for early-stage non-small cell lung cancer (NSCLC) — neoadjuvant chemotherapy plus a perioperative immune checkpoint inhibitor — may ...
(RTTNews) - Innate Pharma SA (IPHA) said Friday that IPH5201, an anti-CD39 blocking monoclonal antibody developed in collaboration with AstraZeneca (AZN, AZN.L), will advance into a Phase 2 clinical ...
From the onset of the coronavirus disease 2019 (COVID-19) pandemic, a disease that is caused by infection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), pregnancy has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results